Loading
Life sciences · Journal article
Journal of Translational Medicine · September 2, 2026
Encouraging direction, but not yet definitive.
This preclinical study demonstrates that NRF2 activation suppresses obesity-induced white adipose tissue inflammation by inhibiting the STING pathway, with effects mediated through reduced mitochondrial DNA leakage in mature adipocytes. The work identifies a depot-specific regulatory axis—robust anti-inflammatory effects in visceral but minimal effects in subcutaneous fat—driven by differential adipogenicity, proposing the NRF2–STING axis as a therapeutic target for metabolic disease.
Preclinical mechanistic study combining in vitro differentiated adipocytes with in vivo high-fat diet-induced obese mice. High-fat diet-induced obese mice and differentiated adipocytes in vitro; setting and key eligibility criteria not detailed in abstract.. Intervention: Pharmacological NRF2 activation (CDDO-Im); in situ AAV-pAdipoq-mediated NRF2 overexpression in white adipose tissue; in vitro NRF2 activation in palmitic acid-stimulated adipocytes.. Compared with: Vehicle or control conditions; in situ AAV-pAdipoq-mediated NRF2 knockdown or STING overexpression as loss-of-function comparators..
NRF2 activity was reduced in obese WAT and mature adipocytes compared to lean controls. In vitro NRF2 activation attenuated oxidative stress and inflammation by suppressing STING signaling, with diminished cytosolic mtDNA leakage and inhibited STING translocation. In vivo pharmacological NRF2 activation with CDDO-Im significantly improved obesity, insulin resistance, and systemic inflammation.
In vivo pharmacological NRF2 activation with CDDO-Im significantly improved obesity, insulin resistance, and systemic inflammation.
This work establishes a novel mechanistic link between NRF2 and obesity-related inflammation amenable to pharmacological targeting. However, findings are preclinical; clinical translation requires human validation and randomized controlled trials before informing clinical practice.
Mechanistically rigorous preclinical study with in vitro and in vivo evidence in mouse models showing NRF2 activation suppresses obesity-related inflammation via STING inhibition, but lacks human data and clinical endpoints needed for stronger evidence grade.
As stated by the source record.
Quoted from the source exactly as published.
This work establishes a novel mechanistic link between NRF2 and obesity-related inflammation amenable to pharmacological targeting. However, findings are preclinical; clinical translation requires human validation and randomized controlled trials before informing clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Obesity-induced oxidative stress triggers the cGAS-STING pathway via mitochondrial DNA (mtDNA) leakage, driving chronic white adipose tissue (WAT) inflammation. Nuclear factor erythroid 2-related factor 2 (NRF2) is a master transcriptional regulator of antioxidant responses, but whether it can serve as an endogenous negative regulator of the STING-driven inflammatory cascade in adipocytes remains poorly defined. This study investigated the role of NRF2 in modulating the STING pathway to alleviate adipose inflammation and explored how fat depot heterogeneity influences this regulatory axis. NRF2 activity was assessed in the WAT of high-fat diet-induced obese mice and in differentiated adipocytes. In vitro, palmitic acid-stimulated adipocytes were used to evaluate the anti-inflammatory effects of NRF2 activation. Mechanistic studies involved genetic knockdown/overexpression, transcriptomic profiling, and assessments of cytosolic mtDNA levels and STING translocation. In vivo, obese mice were treated with the NRF2 activator CDDO-Im, alongside in situ AAV-p Adipoq -mediated NRF2 knockdown or STING overexpression in WAT, to assess metabolic phenotypes and inflammatory responses. NRF2 activity was reduced in obese WAT and mature adipocytes. In vitro, NRF2 activation attenuated oxidative stress and inflammation by suppressing the STING cascade, characterized by diminished cytosolic mtDNA leakage and subsequent inhibition of STING-dependent translocation and effector signaling. In vivo, pharmacological NRF2 activation significantly improved obesity, insulin resistance, and systemic inflammation. These effects were largely abolished by local adipocyte-specific NRF2 knockdown or STING overexpression. Transcriptomic profiling revealed depot-specific effects: NRF2 robustly suppressed inflammatory pathways in visceral epididymal WAT (eWAT) but had minimal impact in subcutaneous inguinal WAT (iWAT). Consistently, NRF2 downregulated STING in eWAT while upregulating it in iWAT. Multiplex imaging and cell-fraction analysis demonstrated that active STING signaling operates predominantly in mature adipocytes. Adipocyte differentiation status was identified as a key determinant of this divergence. Due to higher adipogenic potential, NRF2 preferentially inhibited adipogenesis in iWAT, leading to an enrichment of immature adipocytes expressing high STING levels. NRF2 is a critical negative regulator of STING signaling that mitigates obesity-associated inflammation. This study identifies the NRF2–STING axis as a therapeutic target and demonstrates that inherent differences in adipogenicity dictate depot-specific pharmacological responses, providing a framework for precision translational medicine in metabolic diseases.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.